Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel recombinant bifunctional fusion protein as well as preparation and application thereof

A fusion protein and dual-function technology, which can be applied in the direction of drug combination, fusion polypeptide, peptide/protein components, etc., can solve the problem of insufficient CD47 affinity and activity

Active Publication Date: 2016-11-23
IMMUNEONCO BIOPHARM (SHANGHAI) CO LTD
View PDF7 Cites 22 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] The binding activity of SIRPα-Fc and SIRPαD1-Fc to CD47 has been reported before (Lee WY et al, 2007), but their affinity activity with the target CD47 is insufficient

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel recombinant bifunctional fusion protein as well as preparation and application thereof
  • Novel recombinant bifunctional fusion protein as well as preparation and application thereof
  • Novel recombinant bifunctional fusion protein as well as preparation and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0074] Experimental materials and methods

[0075] 1. Construction of SIRPα-Fc and SIRPαD1-Fc expression vectors

[0076] The expression vector used was pIg-Tail (R&D Systems). Use primer 1 (SEQ ID No.: 9) and primer 2 (SEQ ID No.: 10), primer 1 (SEQ ID No.: 9) and primer 3 (SEQ ID No.: 11) respectively the outer membrane of SIRPα The end and SIRPαD1 gene coding sequence from THP-1 ( TIB-202 TM ) cells, and the PCR products were respectively cloned into the HindIII / EcoRI sites of the improved pIg-Tail vector to form pSIRPα-Fc and pSIRPαD1-Fc vectors.

[0077] 2. Construction of HY03M and HY03MM expression vectors

[0078] The SIRPαD1 gene sequence carrying the N89A mutant was sent to Nanjing GenScript Synthesis (Project No.: 7009323-1), and the synthesized gene was cloned into the HindIII / EcoRI site of the pIg-Tail vector to form the HY03M expression vector. Using primer 4 (SEQ ID No.: 12) and primer 5 (SEQ ID No.: 13), through site-directed mutagenesis PCR, the gene seq...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention discloses a genetic recombinant fusion protein. Tumors can be eliminated through two mechanisms, one mechanism refers to blockage of inhibitory signals for tumor-cell-induced macrophage, and the other mechanism refers to direct activation of the phagocytosis of the macrophage. The protein (SIRPalphaD1-Fc (signal-regulatory proteins alpha D1-Fc)) is formed by connecting human SIRPalphaD1 (a first Ig sample region of an outer membrane end of SIRPalpha) with an Fc segment of human IgG1. The invention provides a nucleotide molecule encoding the recombinant bifunctional fusion protein, an expression vector expressing the protein, a method for preparing the protein and a method for treating CD47 overexpression-related diseases. The protein belongs to a homodimer and has the molecular weight being 90 kDa.

Description

technical field [0001] The invention relates to a recombinant bifunctional fusion protein and its preparation method and application, especially its application in tumor treatment. Background technique [0002] In order to accelerate their own growth, tumor cells often "invent" some ways to escape the host's immune surveillance of tumor cells. The known pathways include three: 1) Evasion from the immune surveillance of T lymphocytes. Tumor cells often highly express the membrane proteins PD-L1 and PD-L2, and PD-L1 / PD-L2 can bind to PD-1 on the surface of T cell membranes to induce T cell apoptosis. 2) Evasion of immune surveillance by natural killer (NK) cells. There is a protein NKG2D on the cell membrane of NK cells that can activate NK cells. When NKG2D combines with MICA / MICB on the tumor cell membrane, it can activate NK cells to kill tumor cells. However, tumor cells themselves have a mechanism that can promote the shedding of MICA / MICB from the cell membrane, and t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K19/00C12N15/62C12N15/63C12N5/10A61K39/395A61P35/00A61P35/02A61P29/00A61P19/02A61P1/00A61P11/06A61P37/08
CPCA61K39/395C07K19/00C12N5/10C12N15/62C12N15/63A61P11/06A61P19/02A61P35/02A61P1/00A61P35/00A61K38/00C07K14/4702C07K2319/30C07K2319/74
Inventor 刘利娟景德强王华
Owner IMMUNEONCO BIOPHARM (SHANGHAI) CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com